William A. Zammarrelli

William A. Zammarrelli

Auto-generated profile, based on publicly available information

William A. Zammarrelli

Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
AGAngela K. Green
Angela K. Green
QZQin Zhou
Qin Zhou
AIAlexia Iasonos
Alexia Iasonos
WZWilliam A. Zammarrelli
William A. Zammarrelli
BWBritta Weigelt
Britta Weigelt
VMVicky Makker
Vicky Makker
Purpose: Inhibition of the cyclin D–cyclin-dependent kinase (CDK)4/6–INK4–retinoblastoma pathway can overcome acquired or de novo treatment resistance to endocrine monotherapy. Responses to endocrine monotherapy in advanced endometrial cancer are suboptimal, perhaps due to genomic alterations that promote estrogen receptor–independent cyclin D1–CDK4/6 activation. We hypothesized that the addition of abemaciclib, a CDK4/6 kinase inhibitor, to antiestrogen therapy with fulvestrant would be an effective therapeutic strategy in patients with advanced or recurrent endometrial cancer. Patients and Methods: In this phase II study, patients with advanced or recurrent endometrial cancer received 150 mg of abemaciclib orally twice daily with 500 mg of fulvestrant intramuscularly monthly with a 2-week loading dose. Eligibility included estrogen receptor or progesterone receptor expression ≥1% by IHC, measurable disease, ≤2 prior lines of chemotherapy, and ≤1 prior lines of hormonal therapy. The primary endpoint was the objective response rate by RECIST v1.1. Results: Twenty-seven patients initiated therapy, and 25 were evaluable for efficacy. Eleven patients achieved partial response; 10 responses (91%) were in copy number–low/no specific molecular profile tumors, 1 response (9%) was in a microsatellite instability–high tumor, and no responses were observed in copy number–high/TP53abnormal tumors. The objective response rate was 44% (90% confidence interval, 27.0%–62.1%). The median duration of response was 15.6 months. The median progression-free survival was 9.0 months (90% confidence interval, 1.8–20.4). The most common grade ≥3 treatment-related adverse events were neutropenia (26%) and anemia (19%); no new safety signals were identified. Conclusions: The combination of abemaciclib and fulvestrant has promising activity with durable responses in advanced or recurrent endometrial cancer; a randomized trial is planned. See related commentary by Garg and Oza, p. 2073

1 October 2022 in JCO Precision Oncology
Verified
Journal Article
Closed access
WZWilliam A. Zammarrelli
William A. Zammarrelli
SKSarah H. Kim
Sarah H. Kim
APArnaud Da Cruz Paula
Arnaud Da Cruz Paula
EREric Rios-Doria
Eric Rios-Doria
SESarah Ehmann
Sarah Ehmann
JMJennifer J. Mueller
Jennifer J. Mueller
PURPOSE: The role of adjuvant therapy in stage I grade 3 endometrioid endometrial carcinoma (EEC) is debatable. We sought to define the agreement between Post Operative Radiation Therapy in Endometrial Carcinoma 1 (PORTEC-1) high-intermediate risk (HIR) and Gynecologic Oncology Group (GOG)-99 HIR criteria, assess their concordance with The Cancer Genome Atlas molecular subtypes, and evaluate oncologic outcomes in this population. METHODS: We identified patients with stage I grade 3 EECs who underwent surgical staging at our institution from January 2014 to January 2020. Patients were stratified into PORTEC-1 HIR, GOG-99 HIR, and The Cancer Genome Atlas molecular subtypes. Adjuvant treatment, and progression-free survival (PFS), and overall survival (OS) were analyzed. RESULTS: Seventy-five patients were included. The agreement between PORTEC-1 and GOG-99 HIR classification was 68% (95% CI, 56.2 to 78.3), with a kappa of 0.36 ( P = .001). There was no agreement between PORTEC-1 or GOG-99 HIR classification and a dichotomized molecular classification (copy number-high [CN-H] v other subtypes), with a kappa of 0.03 ( P = .39) and −0.03 ( P = .601), respectively. There was no difference in PFS between PORTEC-1 HIR and non-HIR (HR, 10.9; 95% CI, 0.28 to 4.21) or between GOG-99 HIR and non-HIR (HR, 1.22; 95% CI, 0.32 to 4.6) stage I grade 3 EECs. Patients with CN-H compared with non-CN-H EEC had worse PFS (HR, 5.67; 95% CI, 1.73 to 18.63) and OS (HR, 5.05; 95% CI, 1.13 to 22.5). CONCLUSION: In surgically staged patients with stage I grade 3 EEC, PORTEC-1 and GOG-99 HIR criteria were not prognostic and did not identify CN-H patients. Patients with CN-H EEC had worse PFS and OS compared with those with other molecular subtypes. The integration of the molecular classification with recognized clinicopathologic factors may identify patients with higher-risk stage I grade 3 EEC who benefit from additional therapy.

3 June 2025
Verified
Other
Open access
PDF file
AGAngela K. Green
Angela K. Green
QZQin Zhou
Qin Zhou
AIAlexia Iasonos
Alexia Iasonos
WZWilliam A. Zammarrelli
William A. Zammarrelli
BWBritta Weigelt
Britta Weigelt
VMVicky Makker
Vicky Makker
Association Between Molecular Biomarkers and Clinical Activity as Measured by Objective Response (OR)


3 June 2025
Verified
Other
Open access
PDF file
AGAngela K. Green
Angela K. Green
QZQin Zhou
Qin Zhou
AIAlexia Iasonos
Alexia Iasonos
WZWilliam A. Zammarrelli
William A. Zammarrelli
BWBritta Weigelt
Britta Weigelt
VMVicky Makker
Vicky Makker
Representativeness of Study Participants

3 June 2025
Verified
Other
Open access
PDF file
AGAngela K. Green
Angela K. Green
QZQin Zhou
Qin Zhou
AIAlexia Iasonos
Alexia Iasonos
WZWilliam A. Zammarrelli
William A. Zammarrelli
BWBritta Weigelt
Britta Weigelt
VMVicky Makker
Vicky Makker
Molecular Subtyping of Endometrial Cancer